Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390472 | 0.90 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL29222095 | 0.90 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL4468362 | 0.90 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL2198040 | 0.90 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL15731577 | 0.90 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL20514898 | 0.90 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL31153617 | 0.90 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL7852372 | 0.90 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL26765842 | 0.87 | CHRM2 (0.42) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL19214839 | 0.83 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | KI PHARMACEUTICALS, LLC | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | CYP19A1, PGR, CYP21A2 | CHRM2 3842/4885CHRM1 4697/4885CHRM3 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.